What is the primary impact of CLARITIN's switch to OTC status on the company's financial performance?

The switch of CLARITIN to over-the-counter (OTC) status has led to a rapid and material decline in its U.S. prescription sales. While intended to extend the product's lifecycle, this transition significantly reduced revenue from this key product in 2002. The company is now focused on managing the co-existence of OTC CLARITIN, its prescription counterpart CLARINEX, and generic competition in the allergy market.

What are the major legal and regulatory risks facing the company as detailed in the filing?

The company is involved in several significant legal and regulatory matters. These include an FDA consent decree concerning manufacturing practices, which carries substantial financial penalties and operational requirements. Additionally, there are ongoing patent litigations related to key products like CLARITIN and REBETOL, as well as multiple governmental investigations into marketing practices, pricing, and potential antitrust violations. These issues pose a material risk to the company's financial condition and operations.

How is the company addressing competition in its key therapeutic areas, particularly allergy and hepatitis C?

In the allergy segment, the company is navigating the challenges posed by CLARITIN's OTC switch and the introduction of generic alternatives by promoting CLARINEX and managing its OTC CLARITIN strategy. For hepatitis C, while the INTRON franchise (PEG-INTRON and REBETOL) saw significant growth, management acknowledges that a recently approved competing product will likely adversely affect market share. The company is also pursuing collaborations, such as the one with Merck for cholesterol management and respiratory products.

What is the financial impact of the FDA consent decree?

The consent decree requires the company to pay a total of $500 million to the U.S. government, with the first installment paid in May 2002 and the second due in Q2 2003. The decree also includes potential payments of up to $25 million in 2002 and $50 million annually for 2003-2005 if deadlines for revalidation are missed, with an overall cap of $175 million. Failure to certify products by specific dates could result in significant penalties based on a percentage of net domestic sales.

MRK 10-K FY2002 Annual Report — Revenue, Net Income, EPS

Summary

Merck & Co., Inc.'s 2002 10-K filing reveals a company navigating significant shifts, notably the transition of its blockbuster allergy medication, CLARITIN, from prescription to over-the-counter (OTC) status. This strategic move, while intended to extend product lifecycle, led to a sharp decline in U.S. CLARITIN prescription sales in 2002. The company is also facing increased competition and market erosion for other key products like PEG-INTRON and REBETOL combination therapy for hepatitis C. Financially, Schering-Plough reported consolidated net sales of $10.18 billion for 2002, a 4% increase from 2001. However, this growth was tempered by the significant drop in allergy product sales. A major operational and financial concern highlighted is the ongoing consent decree with the FDA regarding Good Manufacturing Practices (GMPs) at certain manufacturing facilities, which includes substantial financial penalties and stringent revalidation requirements. The company also faces numerous legal proceedings and investigations, including patent disputes, antitrust allegations, and inquiries related to marketing practices, which could materially impact future financial results.

Key Highlights

1CLARITIN's transition to OTC status significantly impacted prescription sales, with U.S. CLARITIN Rx sales falling from $2.7 billion in 2001 to $1.4 billion in 2002.
2Consolidated net sales increased by 4% to $10.18 billion in 2002, though this growth was constrained by product mix shifts and competitive pressures.
3The company entered into a $500 million consent decree with the FDA to resolve GMP compliance issues at certain manufacturing facilities, involving phased payments and strict revalidation schedules.
4Significant legal and regulatory challenges are ongoing, including patent litigation for CLARITIN and REBETOL, various governmental investigations into marketing and pricing practices, and shareholder class-action lawsuits.
5A strategic collaboration with Merck & Co. for cholesterol management products (ZETIA) and respiratory treatments is a key area of development, with ZETIA receiving FDA approval for sale in the U.S.
6Sales from the INTRON franchise (INTRON A, PEG-INTRON, REBETOL) saw substantial growth of 89% in 2002, but face future competition.
7Research and development expenditures remained high, with $1.425 billion spent in 2002, representing approximately 14% of consolidated net sales.

Merck & Co., Inc. Annual Report, Year Ended Dec 31, 2002

Summary

Key Highlights

Frequently Asked Questions